Sebekova K.1, Fierlbeck W.2, Krivosikova Z.1, Schinzel R.3, Dämmrich J.4, Galbavy S. 5, Blazicek P.6, Syrova D.6, Heidland A.7
1Clinic of Pharmacotherapy. Institut of Preventive
and Clinical Medicine. Bratislava. Slovakia
Transactions of the universities of Košice, Biomedical subedition Folia Medica Cassoviensia, 5,1999
In renal hypertrophy (RH) accumulation of extracellular matrix and intracellular proteins is a consequence of enhanced proteosynthesis and decreased protein degradation. If impaired activities of proteolytic enzymes participate in the RH, administration of proteases should exert beneficial effects. This hypothesis was studied in 3 different rat models of progressive renal disease: renovascular hypertension, remnant kidney model, and unilateral ureteral obstruction (UUO) model. The effect of Phlogenzym ( a fixed mixture of trypsin, bromelain, and rutosid) in dose of 12 mg/d administered through 14-45 days was compared to that of the placebo (and angiotensin II receptor 1 antagonist losartan, UUO model). Sham operated healthy rats served as controls. Systemic treatment with proteolytic enzymes showed beneficial effects on renal function (amelioration of proteinuria and partial prevention in rise of serum creatinine), slowed down the development of tubulointerstitial fibrosis and accumulation of collagen in renal cortex, and partially prevented the rise in pro-fibrotic factors, such as urinary TGF-b 1 excretion, and accumulation of advanced glycation end products and markers of lipid peroxidation.
Datum aktualizace stránky: 19. 1. 2016